Therapy Potential of Tailless Bacteriophage ΦHN161 and its Ability in Modulating Inflammation Caused by Bacterial Disease
DOI:
https://doi.org/10.17140/VMOJ-1-107Keywords:
Escherichia coli; Bacteriophage φHN161; Inflammatory cytokine.Abstract
Almost all the phages reported were long-tail or short-tail, belong to the Myoviridae or
Podoviridae phage families, little information was available on tailless bacteriophages and their
biological significance in therapy. Tailless bacteriophage φHN161 in this study was isolated
from sewage water samples. This representative phage displayed a strong ability in eliminating
pathogenic Escherichia coli O161. Mice challenged with E. coli O161 were treated with
different doses of phage φHN161 for comparing sterilization rate and immunological reaction
with those untreated mice in control group. Phage of higher dose was much more effective than
of lower dose in eliminating host cells both in vitro and in vivo, while a lower dose of phage
treatment could drastically reduce inflammation caused by E. coli O161 infection. Altogether,
these observations expanded the diversity of phages that could be utilized as antimicrobial
agents substitute in animals; these findings also reminded people to pay attention to the dosage
of bacteriophages used in therapy.
References
Brussow H. Phage therapy: the Escherichia coli experience. Microbiology. 2005; 151(Pt 7): 2133-2140. doi: 10.1099/ mic.0.27849-0
Biswas B, Adhya S, Washart P, et al. Bacteriophage therapy rescues mice bacteremic from a clinical isolate of vancomycin-resistant Enterococcus faecium. Infect Immun. 2002; 70(1): 204- 210. doi: 10.1128/IAI.70.1.204-210.2002
Bruttin A, Brussow H. Human volunteers receiving Escherichia coli phage T4 orally: a safety test of phage therapy. Antimicrob Agents Chemother. 2005; 49(7): 2874-2878. doi: 10.1128/AAC.49.7.2874-2878.2005
Cheng D, Sun H, Xu J, Gao S. PCR detection of virulence factor genes in Escherichia coli isolates from weaned piglets with edema disease and/or diarrhea in China. Vet Microbiol. 2006; 115(4): 320-328. doi: 10.1016/j.vetmic.2006.02.013
Cerveny KE, DePaola A, Duckworth DH, Gulig PA. Phage therapy of local and systemic disease caused by Vibrio vulnificus in iron-dextran-treated mice. Infect Immun. 2002; 70(11): 6251- 6262. doi: 10.1128/IAI.70.11.6251-6262.2002
Sulakvelidze A, Alavidze Z, Morris JG. Bacteriophage therapy. Antimicrob Agents Chemother. 2001; 45(3): 649-659. doi: 10.1128/AAC.45.3.649-659.2001
Barrow PA, Soothill JS. Bacteriophage therapy and prophylaxis: rediscovery and renewed assessment of potential. Trends Microbiol. 1997; 5(7): 268-271. doi: 10.1016/S0966- 842X(97)01054-8
Capparelli R, Parlato M, Borriello G, Salvatore P, Iannelli D. Experimental phage therapy against Staphylococcus aureus in mice. Antimicrob Agents Chemother. 2007; 51(8): 2765-2773. doi: 10.1128/AAC.01513-06
Lederberg J. Smaller fleas ... ad infinitum: therapeutic bacteriophage redux. Proc Natl Acad Sci U S A. 1996; 93(8): 3167-3168. Web site. http://www.pnas.org/content/93/8/3167. long. Accessed August 20, 2016.
Coward C, Grant AJ, Swift C, et al. Phase-variable surface structures are required for infection of Campylobacter jejuni by bacteriophages. Appl Environ Microbiol. 2006; 72(7): 4638- 4647. doi: 10.1128/AEM.00184-06
Atterbury RJ, Van Bergen MA, Ortiz F, et al. Bacteriophage therapy to reduce salmonella colonization of broiler chickens. Appl Environ Microbiol. 2007; 73(14): 4543-4549. doi: 10.1128/ AEM.00049-07
Barrow P, Lovell M, Berchieri A. Use of lytic bacteriophage for control of experimental Escherichia coli septicemia and meningitis in chickens and calves. Clin Diagn Lab Immunol. 1998; 5(3): 294-298. Web site. http://cvi.asm.org/ content/5/3/294.long. Accessed August 20, 2016
Chibani-Chennoufi S, Sidoti J, Bruttin A, et al. Isolation of Escherichia coli bacteriophages from the stool of pediatric diarrhea patients in Bangladesh. J Bacteriol. 2004; 186(24): 8287-8294. doi: 10.1128/JB.186.24.8287-8294.2004
Smith HW, Huggins MB, Shaw KM. Factors influencing the survival and multiplication of bacteriophages in calves and in their environment. J Gen Microbiol. 1987; 133(5): 1127-1135. doi: 10.1099/00221287-133-5-1127
Chibani-Chennoufi S, Sidoti J, Bruttin A, Kutter E, Sarker S, Brüssow H. In vitro and in vivo bacteriolytic activities of Escherichia coli phages: implications for phage therapy. Antimicrob Agents Chemother. 2004; 48(7): 2558-2569. doi: 10.1128/AAC.48.7.2558-2569.2004
Sillankorva S, Neubauer P, Azeredo J. Isolation and characterization of a T7-like lytic phage for Pseudomonas fluorescens. BMC Biotechnol, 2008; 8: 80. doi: 10.1186/1472- 6750-8-80
Sheng H, Knecht HJ, Kudva IT, Hovde CJ. Application of bacteriophages to control intestinal Escherichia coli O157:H7 levels in ruminants. Appl Environ Microbiol. 2006; 72(8): 5359- 5366. doi: 10.1128/AEM.00099-06
Watanabe R, Matsumoto T, Sano G, et al. Efficacy of bacteriophage therapy against gut-derived sepsis caused by Pseudomonas aeruginosa in mice. Antimicrob Agents Chemother. 2007; 51(2): 446-452. doi: 10.1128/AAC.00635-06
De Paepe M, Taddei F. Viruses life history: Towards a mechanistic basis of a trade-off between survival and reproduction among phages. PLoS Biol. 2006; 4(7): e193. doi: 10.1371/journal.pbio.0040193
Kropinski AM. Phage Therapy-Everything Old is New Again. Can J Infect Dis Med Microbio. 2006; 17(5): 297-306. doi: 10.1155/2006/329465
Merril CR, Biswas B, Carlton R, et al. Long-circulating bacteriophage as antibacterial agents. Proc Natl Acad Sci U S A. 1996; 93(8): 3188-3192. Web site. http://www.pnas.org/ content/93/8/3188.long. Accessed August 20, 2016.
Stenholm AR, Dalsgaard I, Middelboe M. Isolation and characterization of bacteriophages infecting the fish pathogen Flavobacterium psychrophilum. Appl Environ Microbiol. 2008; 74(13): 4070-4078. doi: 10.1128/AEM.00428-08
Miedzybrodzki R, Fortuna W, Weber-Dabrowska B, Górski A. Phage therapy of staphylococcal infections (including MRSA) may be less expensive than antibiotic treatment. Postepy Hig Med Dosw (Online). 2007; 61: 461-465.
Ma Y, Pacan JC, Wang Q, et al. Microencapsulation of bacteriophage felix O1 into chitosan-alginate microspheres for oral delivery. Appl Environ Microbiol. 2008; 74(15): 4799-4805. doi: 10.1128/AEM.00246-08
McVay CS, Velasquez M, Fralick JA. Phage therapy of Pseudomonas aeruginosa infection in a mouse burn wound model. Antimicrob Agents Chemother. 2007; 51(6): 1934-1938. doi: 10.1128/AAC.01028-06
Kudva IT, Jelacic S, Tarr PI, Youderian P, Hovde CJ. Biocontrol of Escherichia coli O157 with O157-specific bacteriophages. Appl Environ Microbiol. 1999; 65(9): 3767- 3773. Web site. http://aem.asm.org/content/65/9/3767.long. Accessed August 20, 2016.
O’Flynn G, Ross RP, Fitzgerald GF, Coffey A. Evaluation of a cocktail of three bacteriophages for biocontrol of Escherichia coli O157:H7. Appl Environ Microbiol. 2004; 70(6): 3417-3424. doi: 10.1128/AEM.70.6.3417-3424.2004
Tanji Y, Shimada T, Yoichi M, Miyanaga K, Hori K, Unno H. Toward rational control of Escherichia coli O157:H7 by a phage cocktail. Appl Microbiol Biotechnol. 2004; 64(2): 270-274. doi: 10.1007/s00253-003-1438-9
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
All content published in Veterinary Medicine (VM) is licensed under the Creative Commons Attribution 4.0 International License (CC BY 4.0). This license allows anyone to copy, distribute, transmit, and adapt the work — including for commercial purposes — provided appropriate credit is given to the original author(s) and source.
